Bio-Rad Laboratories, Inc. Class A Common Stock vs Stitch Fix Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Stitch Fix Inc trades at $3.53 (market cap $495.68M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 16.2× Stitch Fix Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| BIO | SFIX | |
|---|---|---|
Market Cap | $8.04B | $495.68M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $5.83 |
52-Week Low | $241.71 | $3.06 |
Enterprise Value | $7.85B | $383.39M |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Stitch Fix (SFIX) trades at $3.62, up 1.69% on the day, as the stock shows signs of stabilization after a significant YTD decline. Recent quarters have seen narrowing losses, with Q1 2026 EPS beating expectations, and the company has returned to active client growth. The technical picture remains bearish, but improving fundamentals and AI-driven personalization efforts are key highlights. Analyst consensus is mixed, with a $4.75 price target suggesting potential upside from current levels.
The outlook for SFIX hinges on its turnaround execution, with revenue stabilization and margin improvement offering a path to profitability. Key risks include consumer spending pressures and competitive threats. While the stock trades near historic lows, positive earnings surprises and strategic AI investments present a speculative opportunity for value-oriented investors, balanced by ongoing net losses and cash flow challenges.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →